MedTrace Logo

Evaluating Emetine for Viral Outbreaks (EVOLVE)

NCT05889793 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-01-23

No results posted yet for this study

Summary

The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to:

* Take Emetine 6mg orally for 10 consecutive days
* Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms
* Undergo blood draws

Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.

Conditions

Interventions

DRUG

Emetine Hydrochloride

To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.

DRUG

Placebo

Participant takes a placebo for 10 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • Kunchok Dorjee, MBBS, PhD, MPH · Johns Hopkins School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2025-12-15
Completion
2025-12-15
FDA Drug
Yes

Countries

  • United States
  • Nepal

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889793 on ClinicalTrials.gov